amendment to fredik

Subject re: ptd : to make a run soon
Stock Code PTD - PEPTECH LIMITED
Posted 18/05/06 1:24:16 PM - 65 reads
Posted by Fred*ck

IP 211.31.xxx.xxx
Post #1067431 - in reply to msg. #1066973 - splitview




Any body read the report on SS re Humira and Remicade. Its been proven that people who take these drugs run the risk of cancer 3 times more.You can read the report on s.s.




???
yes medcines have side effects and they do get amended and labels change on new side effects as they become known, the drug remicade is not in the same family as vioxx , i personally know some one that was part of trial of infliximab / remicade . read the pdf in the below links.


some links to read
http://www.midwestarthritis.com/html/remicade.htm

http://www.fda.gov/medwatch/SAFETY/2004/remicade_dearhcp.pdf

http://www.drugs.com/remicade.html

http://www.gihealth.com/html/education/drugs/remicade.html

http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a604023.html

http://www.yourlawyer.com/articles/topic/remicade


Rheumatoid arthritis patients taking Abbott Laboratories' blockbuster drug Humira or Johnson & Johnson's Remicade face triple the risk of developing several kinds of cancer and double the risk of getting serious infections, a new study found.

Although such risks are still considered small, the analysis, published in Wednesday's Journal of the American Medical Association, builds on previous reports about the risks associated with the popular anti-TNF antibody class of drugs, which is one of the fastest-growing prescription classes in the nation.

Earlier research focused mostly on one kind of cancer, lymphoma and infections such as tuberculosis and pneumonia. But the new study, led by the Mayo Clinic, found an apparent link to other cancers, including skin, gastrointestinal, breast and lung tumors.

While the drugs' government-approved label mentions some of the risks, the manufacturers said the new study does not prove that the medication is at fault, and they said the research was flawed. Another drug in the class, Enbrel, sold by Amgen Inc., was not mentioned in the study, but analysts say it has disclosed similar risks.